Loading
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
Previous close
$8.34
+$0.25 · +3.09%
Regular session · ET · Market data may be delayed.
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
Day range
Current $8.34
52-week range
Current $8.34
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
91
Deep Value
Sentiment
63
Bullish
Risk
50
Elevated Risk
Momentum
78
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
Day range
Current $8.34
52-week range
Current $8.34
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 53.74M USD | — | −6.65M USD | 6.65M USD | — |
| Gross profit | 53.74M USD | — | −6.65M USD | 6.65M USD | — |
| Research and development | 19.16M USD | 48.14M USD | 31.73M USD | 35.81M USD | 29.93M USD |
| Selling, general, and administrative | 17.68M USD | 17.96M USD | 9.88M USD | 10.06M USD | 6.76M USD |
| Operating expenses | 36.84M USD | 66.1M USD | 41.6M USD | 45.88M USD | 36.69M USD |
| Interest income | 2.2M USD | 3.9M USD | — | — | — |
| Interest expense | 1.1M USD | 1.1M USD | — | — | — |
| Depreciation and amortization | 391K USD | 487K USD | 499K USD | 370K USD | 9.54M USD |
| Operating income | 16.9M USD | −66.1M USD | −48.26M USD | −39.23M USD | −36.69M USD |
| Net income | 29.82M USD | −47.73M USD | −53.74M USD | −42.81M USD | −37.56M USD |
Company facts updated Oct 11, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$36.50
337.65% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Avantis U.S. Small Cap Value ETFAVUV4.28M0.01%30.85B USD0.25%$119.64-0.41%
First Trust Dow Jones Select MicroCap Index FundFDM743.38K0.28%261.14M USD0.65%$88.39-0.74%
Dimensional - US Small Cap ETFDFAS330.86K0.00%33.87B USD0.31%$78.35+0.32%
Dimensional - US Targeted Value ETFDFAT269.29K0.00%30.12B USD0.33%$67.27-0.43%
iShares Micro-Cap ETFIWC244.75K0.02%1.32B USD0.60%$183+0.11%
Avantis U.S. Small Cap Equity ETFAVSC230.14K0.01%3.08B USD0.25%$69.98+0.03%
Avantis U.S. Equity ETFAVUS144.47K—14.86B USD0.15%$130.52+0.35%
Hartford Multifactor Small Cap ETFROSC96.28K0.20%47.48M USD0.34%$54.20-0.15%Avantis U.S. Small Cap Value ETFAVUVFirst Trust Dow Jones Select MicroCap Index FundFDMDimensional - US Small Cap ETFDFASDimensional - US Targeted Value ETFDFATiShares Micro-Cap ETFIWCAvantis U.S. Small Cap Equity ETFAVSCAvantis U.S. Equity ETFAVUSHartford Multifactor Small Cap ETFROSCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
